European Journal of Biomedical and Pharmaceutical Sciences

PHARMACOTHERAPEUTIC EVALUATION OF SACUBITRIL WITH VALSARTAN IN HEART FAILURE PATIENTS

*Dr. Mohammed Ashfaq Hussain, Tahmeena Tabassum, Fatima Farooq, Mohammed Abdullah Ali, Ayesha Fatima Sohail, Dr. C. Raghu and Anupama Koneru

ABSTRACT

Background: In patients with HFrEF, treated with sacubitril/valsartan, the treatment benefits were seen which reflects the LV reverse remodelling and predicts the prognosis. Objective: The purpose of this study was to analyse the pharmacotherapeutic evaluation of sacubitril/valsartan in HF patients. Methodology: This prospective observational study was performed in the Department of Cardiology, in Aster Prime Hospital, Ameerpet, Hyderabad. The echo parameters such as ejection fraction, mitral regurgitation, diastolic dysfunction, and cardiac enzyme, NT- pro BNP, adverse events, NYHA Classification and quality of life using KCCQ-12 score were obtained at baseline and follow-up was done after 3 months. The data recorded were statistically analysed using SPSS version 2020, Chi-square test, dependent-t test and Pearson’s correlation. Results: Analysis was done in a sample size of 88 patients. Statistical improvement was noticed in ejection fraction, mitral regurgitation and diastolic dysfunction, with a P-value of (< 0.0001), (0.0080) and (0.0008) respectively, and NT- pro BNP levels was reduced with a P-value of (<0.0001). There is a direct proportional relationship in improvement of KCCQ score with NYHA classification. In this study, it was analysed that 19% of patients improved to NYHA Class 1 after treatment. The impact of sacubitril/ valsartan on KCCQ score domains, the total symptom frequency score, clinical summary score, and overall score show statistical improvement over 3 months, with a P-value of (< 0.0001). Conclusion: This study concludes, that after initiation of sacubitril/valsartan, significant changes were observed in echo parameters, and KCCQ-12 score with respect to NYHA class, which minimizes the chances of death and rehospitalization due to cardiovascular complications, with minimal adverse effects thereby indicating improvement in the quality of life and overall health status of the patients.

Keywords: Sacubitril/ valsartan, ejection fraction, NT- pro BNP, Heart failure, NYHA Classification, and KCCQ- 12 score.